About DnaJ homolog subfamily B member 2
DnaJ homolog subfamily B member 2 (DNAJB2) is a protein
from Homo sapiens identified by UniProt accession
P25686, 324 residues long.
MolForge cross-references it against 0 known binders and
68 disease associations.
Target properties
| Protein name | DnaJ homolog subfamily B member 2 |
| UniProt accession | P25686 |
| Gene | DNAJB2 |
| Organism | Homo sapiens |
| Length | 324 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (68)
Diseases linked to this target (Open Targets).
- neuronopathy, distal hereditary motor, autosomal recessive 5 · score 0.73
- Spinal muscular atrophy with respiratory distress type 1 · score 0.65
- Charcot-Marie-Tooth disease axonal type 2T · score 0.50
- genetic disorder · score 0.47
- charcot-marie-tooth disease, axonal, type 2t · score 0.37
- X-linked Charcot-Marie-Tooth disease type 1 · score 0.34
- Charcot-Marie-Tooth disease X-linked dominant 1 · score 0.34
- neurodegenerative disease · score 0.33
- body mass index · score 0.25
- Charcot-Marie-Tooth disease · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P25686-F1 | alphafold | PREDICTED | 67.35 | — |
Amino-acid sequence (324 residues)
MASYYEILDV PRSASADDIK KAYRRKALQW HPDKNPDNKE FAEKKFKEVA EAYEVLSDKH KREIYDRYGR EGLTGTGTGP SRAEAGSGGP GFTFTFRSPE EVFREFFGSG DPFAELFDDL GPFSELQNRG SRHSGPFFTF SSSFPGHSDF SSSSFSFSPG AGAFRSVSTS TTFVQGRRIT TRRIMENGQE RVEVEEDGQL KSVTINGVPD DLALGLELSR REQQPSVTSR SGGTQVQQTP ASCPLDSDLS EDEDLQLAMA YSLSEMEAAG KKPAGGREAQ HRRQGRPKAQ HQDPGLGGTQ EGARGEATKR SPSPEEKASR CLIL
Explore DnaJ homolog subfamily B member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets